Better understanding of dissolution behaviour of amorphous drugs by in situ solid-state analysis using Raman spectroscopy.
暂无分享,去创建一个
L Peltonen | C. Strachan | J. Yliruusi | K. Kogermann | M. Savolainen | J. Aaltonen | J Yliruusi | L. Peltonen | A. Heinz | K Kogermann | M Savolainen | A Heinz | J Aaltonen | C Strachan | L. Peltonen | Karin Kogermann
[1] J. Rantanen,et al. Influence of polymorphic form, morphology, and excipient interactions on the dissolution of carbamazepine compacts. , 2007, Journal of pharmaceutical sciences.
[2] Yousef Javadzadeh,et al. The effect of type and concentration of vehicles on the dissolution rate of a poorly soluble drug (indomethacin) from liquisolid compacts. , 2005, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.
[3] J. Yates,et al. Structural Studies of the Polymorphs of Carbamazepine, Its Dihydrate, and Two Solvates , 2005 .
[4] Lian Yu,et al. Inhibiting surface crystallization of amorphous indomethacin by nanocoating. , 2007, Langmuir : the ACS journal of surfaces and colloids.
[5] M. Anttila,et al. Pharmacokinetics and dissolution of two crystalline forms of carbamazepine , 1983 .
[6] C. Strachan,et al. A theoretical and spectroscopic study of carbamazepine polymorphs , 2004 .
[7] M. B. James,et al. The influence of thermal and mechanical preparative techniques on the amorphous state of four poorly soluble compounds. , 2005, Journal of pharmaceutical sciences.
[8] George Zografi,et al. The Molecular Mobility of Supercooled Amorphous Indomethacin as a Function of Temperature and Relative Humidity , 1998, Pharmaceutical Research.
[9] P. Cox,et al. γ‐Indomethacin at 120 K , 2003 .
[10] C. Strachan,et al. Characterizing the conversion kinetics of carbamazepine polymorphs to the dihydrate in aqueous suspension using Raman spectroscopy. , 2006, Journal of pharmaceutical and biomedical analysis.
[11] S. Yamamura,et al. Glassy state of pharmaceuticals. II. Bioinequivalence of glassy and crystalline indomethacin. , 1987, Chemical & pharmaceutical bulletin.
[12] R. Suryanarayanan,et al. Use of Glancing Angle X-Ray Powder Diffractometry to Depth-Profile Phase Transformations During Dissolution of Indomethacin and Theophylline Tablets , 2004, Pharmaceutical Research.
[13] N. Kaneniwa,et al. Physicochemical characterization of indomethacin polymorphs and the transformation kinetics in ethanol. , 1985, Chemical & pharmaceutical bulletin.
[14] T. Nagai,et al. Stability and several physical properties of amorphous and crystalline form of indomethacin. , 1980, Chemical & pharmaceutical bulletin.
[15] E. Laine,et al. Formation of dihydrate from carbamazepine anhydrate in aqueous conditions , 1984 .
[16] Bruno C. Hancock,et al. Crystallization of indomethacin from the amorphous state below and above its glass transition temperature. , 1994, Journal of pharmaceutical sciences.
[17] Bruno C. Hancock,et al. What is the True Solubility Advantage for Amorphous Pharmaceuticals? , 2000, Pharmaceutical Research.
[18] Jukka Rantanen,et al. In situ measurement of solvent-mediated phase transformations during dissolution testing. , 2006, Journal of pharmaceutical sciences.
[19] S. Yamamura,et al. Some physicochemical properties of glassy indomethacin. , 1986, Chemical & pharmaceutical bulletin.
[20] R. Suryanarayanan,et al. In Situ Dehydration of Carbamazepine Dihydrate: A Novel Technique to Prepare Amorphous Anhydrous Carbamazepine , 2000, Pharmaceutical development and technology.
[21] P York,et al. Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates. , 2007, Advanced drug delivery reviews.
[22] A. Matzger,et al. Comparison of the four anhydrous polymorphs of carbamazepine and the crystal structure of form I. , 2003, Journal of pharmaceutical sciences.
[23] Niklas Sandler,et al. Screening for differences in the amorphous state of indomethacin using multivariate visualization. , 2007, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[24] Peter York,et al. Use of in situ FT-Raman spectroscopy to study the kinetics of the transformation of carbamazepine polymorphs. , 2004, Journal of pharmaceutical and biomedical analysis.
[25] R. Barnes,et al. Standard Normal Variate Transformation and De-Trending of Near-Infrared Diffuse Reflectance Spectra , 1989 .
[26] Lian Yu,et al. Surface Crystallization of Indomethacin Below Tg , 2006, Pharmaceutical Research.
[27] K. Morris,et al. Reactivity differences of indomethacin solid forms with ammonia gas. , 2002, Journal of the American Chemical Society.
[28] N. Rodríguez-Hornedo,et al. Solution-mediated phase transformation of anhydrous to dihydrate carbamazepine and the effect of lattice disorder. , 2002, International journal of pharmaceutics.
[29] Y. Yoshihashi,et al. Estimation of Initial Dissolution Rate of Drug Substance by Thermal Analysis: Application for Carbamazepine Hydrate , 2002, Pharmaceutical development and technology.
[30] S. Byrn. Solid state chemistry of drugs , 1982 .
[31] H. Brittain. Polymorphism in Pharmaceutical Solids , 1999 .
[32] Thomas Rades,et al. Quantifying ternary mixtures of different solid-state forms of indomethacin by Raman and near-infrared spectroscopy. , 2007, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[33] M. Otsuka,et al. Effect of environmental humidity on the transformation pathway of carbamazepine polymorphic modifications during grinding , 1999 .
[34] Kati Pöllänen,et al. Establishing quantitative in-line analysis of multiple solid-state transformations during dehydration. , 2008, Journal of pharmaceutical sciences.
[35] D. Grant. THEORY AND ORIGIN OF POLYMORPHISM , 1999 .
[36] Kati Pöllänen,et al. Qualitative in situ analysis of multiple solid-state forms using spectroscopy and partial least squares discriminant modeling. , 2007, Journal of pharmaceutical sciences.
[37] J. Reboul,et al. 5H‐Dibenz[b,f]azépinecarboxamide‐5 (carbamazépine) , 1981 .
[38] W. Tong,et al. Impact of solid state properties on developability assessment of drug candidates. , 2004, Advanced drug delivery reviews.
[39] D. Brooke,et al. Heat of fusion measurement of a low melting polymorph of carbamazepine that undergoes multiple-phase changes during differential scanning calorimetry analysis. , 1991, Journal of pharmaceutical sciences.
[40] G. Zografi,et al. Effects of sorbed water on the crystallization of indomethacin from the amorphous state. , 1997, Journal of pharmaceutical sciences.
[41] C. Strachan,et al. A theoretical and spectroscopic study of γ‐crystalline and amorphous indometacin , 2007 .
[42] S. Itai,et al. Physicochemical properties and bioavailability of carbamazepine polymorphs and dihydrate. , 2000, International journal of pharmaceutics.
[43] Geoff G. Z. Zhang,et al. Phase transformation considerations during process development and manufacture of solid oral dosage forms. , 2004, Advanced drug delivery reviews.